0
0
0
Hatch-Waxman Improvement Act of 2022
12/29/2022, 5:33 PM
Congressional Summary of S 4378
Hatch-Waxman Improvement Act of 2022
This bill extends through FY2026 provisions that establish a period of market exclusivity for certain new drugs with single enantiomers (i.e., one of a pair of molecules that are mirror images of one another).
Read the Full Bill
Current Status of Bill S 4378
Bill S 4378 is currently in the status of Bill Introduced since June 13, 2022. Bill S 4378 was introduced during Congress 117 and was introduced to the Senate on June 13, 2022. Bill S 4378's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of June 13, 2022
Bipartisan Support of Bill S 4378
Total Number of Sponsors
1Democrat Sponsors
0Republican Sponsors
1Unaffiliated Sponsors
0Total Number of Cosponsors
0Democrat Cosponsors
0Republican Cosponsors
0Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill S 4378
Primary Policy Focus
HealthAlternate Title(s) of Bill S 4378
Hatch-Waxman Improvement Act of 2022
Hatch-Waxman Improvement Act of 2022
A bill to reauthorize a provision of the Federal Food, Drug, and Cosmetic Act pertaining to drugs containing single enantiomers.
Comments
Sponsors and Cosponsors of S 4378
Latest Bills
Medal of Sacrifice Act
Bill HR 3497January 29, 2026
Protect Infant Formula from Contamination Act
Bill S 272January 29, 2026
Women and Lung Cancer Research and Preventive Services Act of 2025
Bill S 1157January 29, 2026
Rural Hospital Cybersecurity Enhancement Act
Bill S 2169January 29, 2026
Tyler’s Law
Bill S 921January 29, 2026
CLEAR Path Act
Bill S 2132January 29, 2026
Northern Mariana Islands Small Business Access Act
Bill HR 3496January 29, 2026
VSAFE Act of 2025
Bill HR 1663January 29, 2026
Reorganizing Government Act of 2025
Bill HR 1295January 28, 2026
Deporting Fraudsters Act of 2026
Bill HR 1958January 28, 2026
FDASLA Act of 2022
Bill S 4348December 29, 2022